PMID- 37484947 OWN - NLM STAT- MEDLINE DCOM- 20230725 LR - 20230725 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 14 DP - 2023 TI - Sex differences in the non-linear association between BMI and LDL cholesterol in type 2 diabetes. PG - 1180012 LID - 10.3389/fendo.2023.1180012 [doi] LID - 1180012 AB - BACKGROUND: A data-based study reported the linear relationship between body mass index (BMI) and low-density lipoprotein cholesterol (LDL-C) in a normal population. However, there were no studies giving the suggestion for diabetes patients limited by sample size. This study aimed to investigate the non-linear dose-response relationship between BMI and LDL-C in type 2 diabetes mellitus (T2DM). METHOD: The study participants registered at the National Metabolic Management Center (MMC) of Beijing Luhe hospital from June 2017 to June 2021. T2DM was diagnosed according to the 1999 World Organization criteria. The generalized additive models (GAMs) were used to investigate the non-linear association between BMI and LDL-C. The relationship between BMI and LDL-C was visualized via the smooth splines function plot by sex. Segmented regressions were fitted to calculate the slopes with different estimated breakpoints. RESULTS: After data cleaning, a total of 2500 participants with T2DM aged 30 to 70 years were included in this study. Compared with females, the spline between BMI and LDL-C showed an Inverted U shape in males. In males, the slopes below and above the breakpoint (26.08. 95% CI: 24.13 to 28.03) were 2.38 (95%CI: 1.06, 3.70) and -0.36 (95%CI: -1.20, 0.48), respectively. CONCLUSION: There was an Inverted U shape association between BMI and LDL-C in male participants with T2DM, for which the LDL-C was increased with BMI in the lean population, while LDL-C gradually tended to be flat or even decreased in the obese population. However, the Inverted U-shape between BMI and LDL-C was not found in female patients with T2DM. CI - Copyright (c) 2023 Li, Cao, Wang, Chai, Ke and Zhao. FAU - Li, Kun AU - Li K AD - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory of Diabetes Research and Care, Capital Medical University, Beijing, China. FAU - Cao, Bin AU - Cao B AD - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory of Diabetes Research and Care, Capital Medical University, Beijing, China. FAU - Wang, Xiaojing AU - Wang X AD - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory of Diabetes Research and Care, Capital Medical University, Beijing, China. FAU - Chai, Tao AU - Chai T AD - Physical Examination Center, Beijing Luhe Hospital, Capital Medical University, Beijing, China. FAU - Ke, Jing AU - Ke J AD - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory of Diabetes Research and Care, Capital Medical University, Beijing, China. FAU - Zhao, Dong AU - Zhao D AD - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory of Diabetes Research and Care, Capital Medical University, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230707 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 0 (Cholesterol, LDL) SB - IM MH - Humans MH - Male MH - Female MH - *Diabetes Mellitus, Type 2/epidemiology/diagnosis MH - Body Mass Index MH - Cholesterol, LDL MH - Risk Factors MH - Sex Characteristics PMC - PMC10360932 OTO - NOTNLM OT - BMI OT - LDL-C OT - generalized additive models OT - sex differences OT - type 2 diabetes mellitus COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/24 06:42 MHDA- 2023/07/25 06:43 PMCR- 2023/01/01 CRDT- 2023/07/24 04:51 PHST- 2023/03/05 00:00 [received] PHST- 2023/06/26 00:00 [accepted] PHST- 2023/07/25 06:43 [medline] PHST- 2023/07/24 06:42 [pubmed] PHST- 2023/07/24 04:51 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2023.1180012 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2023 Jul 7;14:1180012. doi: 10.3389/fendo.2023.1180012. eCollection 2023.